



NOTICE OF MEETING
AND
MANAGEMENT INFORMATION CIRCULAR
FOR
AN ANNUAL GENERAL MEETING
OF THE SHAREHOLDERS OF
NUROSENE HEALTH INC.
TO BE HELD ON
April 1, 2022

Dated as of March 3, 2022

NUROSENE HEALTH INC.
NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS
TO BE HELD ON APRIL 1, 2022

NOTICE IS HEREBY GIVEN that an annual general meeting (the “**Meeting**”) of the holders (the “**Shareholders**”) of Common shares (the “**Common Shares**”) in the capital of Nurosene Health Inc. (the “**Company**”) will be held at the Company’s head office located at 1655 Dupont St Suite 101, Toronto, Ontario M6P 3T1 on Thursday, April 1, 2022 at 5:00p.m. (Eastern Time) for the following purposes:

1. to receive the financial statements of the Company for the year ended September 30, 2021 together with the report of the Company’s auditor thereon;
2. to set the number of directors of the Company at five (5);
3. to elect the directors of the Company, to take office immediately following the meeting, for the ensuing year;
4. to reappoint MNP LLP as auditors of the Company for the ensuing year and to authorize the directors to fix their remuneration; and
5. to transact such other business as may properly be brought before the Meeting or any adjournment or adjournments thereof.

The Information Circular accompanies this Notice. The Information Circular contains details of matters to be considered at the Meeting. The Board of Directors of the Company has fixed February 25, 2022 as the record date for determining the Shareholders who are entitled to vote at the Meeting. Only holders of Common Shares at the close of business on February 25, 2022 will be entitled to receive notice of and to vote at the Meeting.

Please Read This Important Notice

To mitigate risks related to the rapidly evolving global COVID-19 (coronavirus) public health emergency to Shareholders, employees of the Company and other stakeholders, and based on government recommendations to avoid large gatherings, the Company is providing access to the Meeting by telephone conference call. **In light of COVID-19, we strongly encourage Shareholders to vote in advance of the Meeting rather than appearing in person, or appointing an alternate proxyholder to attend the Meeting in person.**

Shareholders who dial in to the telephone conference call will be able listen to the Meeting and ask questions regardless of their geographic location or particular circumstances they may be facing as a result of COVID-19. **However, registered Shareholders and duly appointed proxyholders will not be able to vote via the telephone conference call. In light of COVID-19, we strongly encourage Shareholders to vote in advance of the Meeting in accordance with the instructions provided in the management information circular accompanying this Notice of Meeting, and Shareholders are encouraged NOT to attend the Meeting in person if at all possible.**

Shareholders may access the telephone conference call as follows:

Dial-in: [+1 778 907 2071](tel:+17789072071); **Meeting ID:** 980 9801 7060

The ability of Shareholders to attend the Meeting in person is subject to any governmental orders applicable at the time of the Meeting which might prevent or restrict Shareholders from attending in person. Please do not attend the Meeting in person if you are experiencing any cold or flu-like symptoms, or if you or someone with whom you have been in close contact has had COVID-19 within five (5) days prior to the Meeting.

The Company is monitoring developments regarding COVID-19. In the event the Company decides any change to the date, time, location or format of the Meeting are necessary or appropriate due to difficulties arising from COVID-19, the Company will promptly notify Shareholders of the change by issuing a news release, a copy of which will be available on SEDAR at www.sedar.com.

Registered Shareholders are requested to date, sign and return the accompanying form of Proxy for use at the Meeting if they are not able to attend the Meeting in person. To be effective, forms of Proxy must be received by the Company's registrar and transfer agent, Odyssey Trust Company, no later than 48 hours (excluding Saturdays, Sundays and holidays) before the time of the Meeting (namely, by 5 p.m. (Eastern Time) on Tuesday, March 29, 2022) or any adjournment thereof at which the Proxy is to be used. Proxies delivered by regular mail or by hand should be addressed to Odyssey Trust Company, the registrar and transfer agent of the Company, at Odyssey Trust Company, 702-67 Yonge St., Toronto, ON, M5E 1J8. To vote by Internet visit the website address shown on the form of Proxy provided. Follow the online voting instructions given to you and vote over the Internet referring to your holder account number and proxy access number provided on the form of Proxy that was delivered to you. To vote by telephone, call the toll-free number shown on the form of Proxy. Using a touch-tone telephone to select your voting preferences, follow the instructions and refer to your holder account number and proxy access number provided on the form of Proxy that was delivered to you. Note that voting by telephone is not available if you wish to appoint a person as a proxy other than someone named on the form of Proxy.

Non-registered Shareholders who are non-objecting beneficial owners and have received a voting instruction form from Broadridge Financial Solutions ("**Broadridge**"), should complete and return the form in accordance with the instructions provided in the Information Circular and on the voting instruction form.

Non-registered Shareholders who have received this Notice and the accompanying Information Circular through a broker, a financial institution, a participant, a trustee or administrator of a self-administered retirement savings plan, retirement income fund, education savings plan or other similar self-administered savings or investment plan registered under the *Income Tax Act* (Canada), or a nominee of any of the foregoing that holds your Common Shares on your behalf (the "**Intermediary**"), please complete and return the materials in accordance with the instructions provided to you by the Intermediary.

The persons named in the enclosed form of Proxy are directors and/or officers of the Company. Each Shareholder has the right to appoint a proxyholder other than such persons, who need not be a Shareholder, to attend and to act for such Shareholder and on such Shareholder's behalf at the Meeting. To exercise such right, the names of the nominees of management should be crossed out and the name of the Shareholder's appointee should be legibly printed in the blank space provided.

BY ORDER OF THE BOARD OF DIRECTORS

"Kevin Taylor"

Kevin Taylor
Chair of the Board of Directors

March 3, 2022



MANAGEMENT INFORMATION CIRCULAR
As at and dated March 3, 2022

**FOR THE ANNUAL GENERAL MEETING OF SHAREHOLDERS
TO BE HELD ON APRIL 1, 2022**

SOLICITATION OF PROXIES

This management information circular (the “Information Circular”) is furnished in connection with the solicitation of proxies by the management of Nurosene Health Inc. (the “Company”) for use at the Annual General Meeting of the Company’s shareholders to be held on April 1, 2022 (the “Meeting”) at the time and place and for the purposes set out in the accompanying Notice of Meeting. While it is expected that the solicitation will be made primarily by mail, proxies may be solicited personally or by telephone by directors, officers and employees of the Company.

All costs of this solicitation will be borne by the Company.

Please Read This Important Notice

To mitigate risks related to the rapidly evolving global COVID-19 (coronavirus) public health emergency to Shareholders, employees of the Company and other stakeholders, and based on government recommendations to avoid large gatherings, the Company is providing access to the Meeting by telephone conference call. **In light of COVID-19, we strongly encourage Shareholders to vote in advance of the Meeting rather than appearing in person, or appointing an alternate proxyholder to attend the Meeting in person.**

Shareholders who dial in to the telephone conference call will be able listen to the Meeting regardless of their geographic location or particular circumstances they may be facing as a result of COVID-19. **However, registered Shareholders and duly appointed proxyholders will not be able to vote via the telephone conference call. In light of COVID-19, we strongly encourage Shareholders to vote in advance of the Meeting in accordance with the instructions provided in the management information circular accompanying this Notice of Meeting, and Shareholders are encouraged NOT to attend the Meeting in person if at all possible.**

Shareholders may access the telephone conference call as follows:

Dial-in: [+1 778 907 2071](tel:+17789072071); **Meeting ID:** 980 9801 7060

The ability of Shareholders to attend the Meeting in person is subject to any governmental orders applicable at the time of the Meeting which might prevent or restrict Shareholders from attending in person. Please do not attend the Meeting in person if you are experiencing any cold or flu-like symptoms, or if you or someone with whom you have been in close contact has had COVID-19 within five (5) days prior to the Meeting.

The Company is monitoring developments regarding COVID-19. In the event the Company decides any change to the date, time, location or format of the Meeting are necessary or appropriate due to difficulties arising from COVID-19, the Company will promptly notify Shareholders of the change by issuing a news release, a copy of which will be available on SEDAR at www.sedar.com.

PROXY INSTRUCTIONS

Shareholders who cannot attend the Meeting in person may vote by Proxy if the Shareholder is a registered Shareholder, or provide voting instruction forms as provided herein if the Shareholder is a non-registered Shareholder, either by mail, by phone or over the internet. Form of Proxy and/or voting instruction forms must be received by Odyssey Trust Company (“**Odyssey**”), the Company’s transfer agent, not later than 5 p.m. (Eastern Time) on March 29, 2022 at its Toronto office located at 702, 67 Yonge Street, Toronto, Ontario M5E 1J8.

A form of Proxy returned to Odyssey will not be valid unless dated and signed by the Shareholder or by the Shareholder’s attorney duly authorized in writing or, if the Shareholder is a corporation or entity, the form of Proxy must be executed by an officer or by an attorney duly authorized in writing. If the form of Proxy is executed by an attorney for an individual Shareholder or by an attorney of a Shareholder that is a corporation or entity, the instrument so empowering the attorney, as the case may be, or a notarial copy thereof, must accompany the form of Proxy. If not dated, the form of Proxy will be deemed to have been dated the date that it is mailed to Shareholders.

The securities represented by forms of Proxy will be voted or withheld from voting in accordance with the instructions of the Shareholder on any ballot that may be called for and, if the Shareholder specifies a choice with respect to any matter to be acted upon, the securities will be voted accordingly. The form of Proxy confers discretionary authority upon the named proxyholder with respect to matters identified in the accompanying Notice of Meeting. If a choice with respect to such matters is not specified, it is intended that the person designated by management in the form of Proxy will vote the securities represented by the form of Proxy in favour of each matter identified in the form of Proxy.

The form of Proxy confers discretionary authority upon the named proxyholder with respect to amendments to or variations in matters identified in the accompanying Notice of Meeting and other matters which may properly come before the Meeting. As at the date of this Information Circular, management is not aware of any amendments, variations, or other matters. If such should occur, the persons designated by management will vote thereon in accordance with their best judgment, exercising discretionary authority.

APPOINTMENT OF PROXYHOLDER

A Shareholder has the right to appoint a person (who need not be a shareholder) to attend and act for such Shareholder and on his, her or its behalf at the Meeting other than the persons designated in the enclosed form of Proxy. If you are returning your form of Proxy to Odyssey, such right may be exercised by inserting in the blank space provided in the enclosed form of Proxy the name of the person to be designated or by completing another proper form of Proxy and delivering it to Odyssey as provided above, or to the Chairman of the Meeting.

REVOCAION OF PROXIES

Forms of Proxy given by Shareholders for use at the Meeting may be revoked prior to their use:

- (a) by depositing an instrument in writing executed by the Shareholder or by such Shareholder’s attorney duly authorized in writing or, if the Shareholder is a corporation, by an officer or attorney thereof duly authorized indicating the capacity under which such officer or attorney is signing at the registered office, 550 Burrard Street, Suite 2900, Vancouver, BC V6C 0A3, at any time up to and including the last business day preceding the day of the Meeting, or if adjourned, any reconvening thereof;
- (b) by an instrument in writing, executed by the Shareholder, that is provided, at the Meeting, to the chair of the Meeting; or
- (c) in any other manner permitted by law.

Only registered Shareholders have the right to revoke a form of Proxy. Non-registered Shareholders that wish to change their voting instruction forms must, in sufficient time in advance of the Meeting, contact Broadridge Financial Solutions (“**Broadridge**”) or their Intermediary (as defined below) to arrange to change their voting instructions.

SPECIAL INSTRUCTIONS FOR VOTING BY NON-REGISTERED SHAREHOLDERS

Only registered Shareholders or duly appointed proxyholders are permitted to vote at the Meeting. Some Shareholders of the Company are “non-registered” Shareholders because the shares they own are not registered in their names but are instead registered in the name of the brokerage firm, bank or trust company through which they purchased the shares. More particularly, a person is not a registered Shareholder in respect of shares which are held on behalf of that person (the “**Non-Registered Shareholder**”), but which are registered in the name of an intermediary (each, an “**Intermediary**” and, collectively, the “**Intermediaries**”) that the Non-Registered Shareholder deals with in respect of the shares. Intermediaries include, among others, banks, trust companies, securities dealers or brokers and trustees or administrators of self-administered RRSP’s, RRIF’s, RESP’s and similar plans, or in the name of a clearing agency (such as The Canadian Depository for Securities Ltd.) of which the Intermediary is a participant.

There are two kinds of Non-Registered Shareholders - those who object to their name being made known to the Company (called OBOs for “**Objecting Beneficial Owners**”) and those who do not object to the Company knowing who they are (called NOBOs for “**Non-Objecting Beneficial Owners**”).

Under National Instrument 54-101 – *Communication with Beneficial Owners of Securities of a Reporting Issuer* (“**NI 54-101**”), the Company is delivering proxy-related materials to NOBOs who have not waived the right to receive them. As a result, NOBOs can expect to receive a voting instruction form (a “**VIF**”), together with the meeting materials, from Broadridge. These VIFs are to be completed and returned to Broadridge in accordance with the instructions. Broadridge is required to follow the voting instructions properly received from NOBOs. Broadridge will tabulate the results of the VIFs received from NOBOs and will provide appropriate instructions at the Meeting with respect to the shares represented by the VIFs they receive. **The Company is not sending proxy-related materials using notice-and-access this year.**

Should a NOBO wish to attend and vote at the Meeting in person, the NOBO must insert the NOBO’s name (or such other person as the NOBO wishes to attend and vote on the NOBO’s behalf) in the blank space provided for that purpose on the VIF and return the completed VIF to Broadridge or the NOBO must submit, to Broadridge, any other document in writing that requests that the NOBO or a nominee of the NOBO be appointed as proxy holder. In such circumstances with respect to forms of Proxy held by management in respect of securities owned by the NOBO so requesting, the Company must arrange, without expense to the NOBO, to appoint the NOBO or a nominee of the NOBO as a proxy holder in respect of those securities. Under NI 54-101, if the Company appoints a NOBO or a nominee of the NOBO as a proxy holder as aforesaid, the NOBO or nominee of the NOBO, as applicable, must be given the authority to attend, vote and otherwise act for and on behalf of management in respect of all matters that may come before the Meeting and any adjournment or continuance thereof, unless corporate law does not permit the giving of that authority. Pursuant to NI 54-101, if the Company appoints a NOBO or its nominee as proxy holder as aforesaid the Company must deposit the form of Proxy within the timeframe specified above for the deposit of form of Proxy if the Company obtains the instructions at least one business day before the termination of that time. **If a NOBO or a nominee of the NOBO is approved as a proxy holder pursuant to such request, the appointed proxy holder will need to attend the Meeting in person in order for their votes to be counted.**

NOBOs that wish to change their vote must in sufficient time in advance of the Meeting contact their Intermediary to arrange to change their vote. NOBOs should carefully follow the instructions of their Intermediaries, including those regarding when and where to complete the VIFs that are to be returned to their Intermediaries.

In accordance with the requirements of NI 54-101, the Company has distributed copies of the meeting materials to the Intermediaries for onward distribution to OBOs. Intermediaries are required to forward the meeting materials to OBOs unless, in the case of certain proxy-related materials, the OBO has waived the right to receive them. Very often, Intermediaries will use service companies to forward the meeting materials to OBOs. With those meeting materials, Intermediaries or their service companies should provide OBOs with a “request for voting instruction form” which, when properly completed and signed by such OBO and returned to the Intermediary or its service company, will constitute voting instructions which the Intermediary must follow. The purpose of this procedure is to permit OBOs to direct the voting of the shares that they beneficially own. The Company does not intend to pay for Intermediaries

to deliver the proxy-related materials and VIFs to OBOs. An OBO will not receive the materials unless the OBO's Intermediary assumes the cost of delivery.

Should an OBO wish to vote at the Meeting in person, the OBO must insert the OBO's name (or such other person as the OBO wishes to attend and vote on the OBO's behalf) in the blank space provided for that purpose on the "request for voting instruction form" and return the completed "request for voting instruction form" to the Intermediary or its service company or the OBO must submit, to their Intermediary, any other document in writing that requests that the OBO or a nominee of the OBO be appointed as proxy holder. In such circumstances an Intermediary who is the registered holder of, or holds a form of Proxy in respect of, securities owned by an OBO is required under NI 54-101 to arrange, without expense to the OBO, to appoint the OBO or a nominee of the OBO as a proxy holder in respect of those securities. Under NI 54-101, if an Intermediary appoints an OBO or the nominee of the OBO as a proxy holder as aforesaid, the OBO or nominee of the OBO, as applicable, must be given the authority to attend, vote and otherwise act for and on behalf of the Intermediary, in respect of all matters that may come before the Meeting and any adjournment or continuance thereof, unless corporate law does not permit the giving of that authority. Pursuant to NI 54-101 an Intermediary who appoints an OBO or its nominee as proxy holder as aforesaid is required under NI 54-101 to deposit the proxy within the timeframe specified above for the deposit of forms of Proxy if the Intermediary obtains the instructions at least one business day before the termination of that time. **If the OBO or a nominee of the OBO is appointed a proxy holder pursuant to such request, the appointed proxy holder will need to attend the Meeting in person in order for their votes to be counted.**

These proxy-related materials are being sent to both registered Shareholders and Non-Registered Shareholders. If you are a Non-Registered Shareholder, and the Company has sent these proxy related materials directly to you, your name and address and information about your holdings of shares have been obtained in accordance with applicable securities requirements from the Intermediary on your behalf.

By choosing to send these materials to you directly, the Company (and not the Intermediary holding on your behalf) has assumed responsibility for: (i) delivering these materials to you; and (ii) executing your proper voting instructions. Please return your voting instruction forms as specified in the "request for voting instructions".

CAUTIONARY STATEMENTS REGARDING FORWARD-LOOKING INFORMATION

This Information Circular contains "forward-looking information" within the meaning of applicable Canadian securities legislation which is based upon Nurosene's current internal expectations, estimates, projections, assumptions and beliefs, and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as "expect", "likely", "may", "will", "should", "intend", "anticipate", "potential", "proposed", "estimate" and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions "may", "would" or "will" happen, or by discussions of strategy. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact. Specifically, this Information Circular contains forward looking statements relating to, among others, implications of the Company's executive compensation.

Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, Nurosene does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and it is not possible for Nurosene to predict all such factors. When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements in Nurosene's Final Long Form Prospectus dated May 20, 2021 and Management's Discussion and Analysis for the year ended September 30, 2021 ("MD&A"), and filed with the applicable Canadian securities regulatory authorities on SEDAR at www.sedar.com. The risk factors and other factors noted in Nurosene's Final Long Form Prospectus and MD&A could cause actual events or results to differ materially from those described in any forward-looking information.

EXCHANGE RATE DATA

Except as otherwise indicated in this Information Circular, references to "dollars", "\$", or "CAD\$" are to Canadian dollars and references to "USD\$" is to U.S. dollars. The following table sets forth, for the periods indicated, the average and period-end rates of exchange for one USD, expressed in Canadian dollars, published by the Bank of

Canada (in the case of the rates for the year ended September 30, 2021 and the year ended September 30, 2020, based on the daily average rates as reported by the Bank of Canada as being in effect at approximately 4:30 p.m. (Eastern time) on each trading day).

| | Year ended September 30, 2021 | Year ended September 30, 2020 |
|-------------------------|--------------------------------------|--------------------------------------|
| High | 1.3349 | 1.4496 |
| Low | 1.2040 | 1.2970 |
| Average rate per period | 1.2642 | 1.3457 |
| Rate at end of period | 1.2741 | 1.3339 |

As of the date of this Information Circular, the last available rate of exchange posted by the Bank of Canada was on March 2, 2022. Such rate of exchange for conversion of U.S. dollars into Canadian dollars was USD\$1.00 equals CAD\$1.27.

VOTING SECURITIES AND PRINCIPAL HOLDERS OF VOTING SECURITIES

The authorized share capital of the Company consists of an unlimited number of Common shares (the “**Common Shares**”), without par value.

As at the date of this Information Circular, 40,282,489 Common Shares were issued and outstanding, each such share carrying the right to one vote at the Meeting.

February 25, 2022 has been fixed by the directors of the Company as the record date (the “**Record Date**”) for the purpose of determining those Shareholders entitled to receive notice of and to vote at the Meeting. A holder of Common Shares at the Record Date is entitled to vote such shares at the Meeting.

A simple majority of affirmative votes cast in person or by form of Proxy at the Meeting is required to pass the resolution(s) described herein as ordinary resolutions.

Under the Articles of the Company, a quorum of Shareholders is present at a meeting of Shareholders if the holders of not less than 5% of the shares entitled to vote at the meeting are present in person or represented by proxy, and at least two persons entitled to vote at the meeting are present at the meeting.

Common Shares

The holders of Common Shares are entitled to receive notice of and attend and vote at all shareholder meetings and each Common Share confers the right to one vote in person or by proxy at all meetings of the shareholders of the Company.

The holders of the Common Shares are entitled to receive such dividends in any financial year as the Company’s Board may by resolution determine.

In the event of the liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, the holders of the Common Shares are entitled to share rateably in the remaining property and assets of the Company as are available for distribution.

Principal Holders of Voting Securities

To the knowledge of the directors and executive officers of the Company, as of the date hereof, only the following

Shareholders beneficially own, or control or direct, directly or indirectly, shares carrying 10% or more of the voting rights attached to all outstanding voting securities of the Company entitled to vote at the Meeting:

| Name | Number of Voting Shares Beneficially Owned, Controlled or Directed (directly or indirectly) | Percentage of Issued and Outstanding Voting Shares as of the date hereof |
|---------------|---|--|
| Joseph Geraci | 4,333,954 | 10.76% |

MATTERS TO BE CONSIDERED AT THE MEETING

I. Financial Statements

The Company's financial statements for the financial year ended September 30, 2021 and the auditors' report thereon will be placed before the Meeting.

II. Setting the Number of Directors

The articles of the Company require a minimum of three (3) directors of the Company. There are currently four (4) directors on the board of directors of the Company (the "Board"). The present term of office of each current director of the Company will expire at the Meeting. At the Meeting, Shareholders will be asked to consider and, if thought advisable, approve a resolution setting the number of directors for the present time at five (5).

It is the intention of the persons named in the enclosed form of proxy, if not expressly directed to the contrary in such form of proxy, to vote such proxies FOR setting the number of directors to be elected at the Meeting at five (5).

III. Election of Directors

At the Meeting, it is proposed that five (5) directors be elected. Each director will hold office until the next annual general meeting of the Company unless that person ceases to be a director before then.

The enclosed form of Proxy permits Shareholders to vote for each nominee on an individual basis. **In the absence of instructions to the contrary, the shares represented by forms of Proxy will be voted FOR the nominees listed below.** Management does not contemplate that any of the nominees will be unable to serve as a director.

The following table sets out the name of each proposed director, the city, province or state and country in which he is ordinarily resident, all offices of the Company now held by him, his principal occupation within the five (5) preceding years, the period of time for which he has been a director of the Company, and the number of shares of the Company beneficially owned by him, directly or indirectly, or over which he exercises control or direction, as of the date of this Information Circular:

| Name, Province/State and Country of Residence and Present Offices Held | Director Since | Principal Occupation | Number of Common Shares ⁽¹⁾ |
|---|--------------------------|--|--|
| <p>KEVIN TAYLOR⁽²⁾⁽³⁾ Ft. Lauderdale, Florida, United States <i>Director and Chairman of the Board</i></p> | <p>November 21, 2021</p> | <ul style="list-style-type: none"> • President and Chief Executive Officer of Prism Equity Group (2008 to present) • President and Chief Executive Officer of TEREI International Limited (2014 to present) | <p>75,000⁽⁴⁾</p> |
| <p>DANIEL GALLUCCI Halifax, Nova Scotia, Canada <i>Director and Chief Innovation Officer</i></p> | <p>March 26, 2021</p> | <ul style="list-style-type: none"> • Owner of Flux Bionetworks (2018 to present) • Founder of Dg2 (2013 to present) | <p>1,717,000</p> |
| <p>SHEETAL JAITLY⁽²⁾⁽³⁾ Toronto, Ontario, Canada <i>Director</i></p> | <p>March 26, 2021</p> | <ul style="list-style-type: none"> • Chief Executive Officer of TribalScale (2015 to present) | <p>Nil⁽⁵⁾</p> |
| <p>ANDREW PARKS⁽²⁾ Toronto, Ontario, Canada <i>Director</i></p> | <p>March 26, 2021</p> | <ul style="list-style-type: none"> • Chief Executive Officer of Fountain Asset Corp (2017 to present) • Portfolio Manager, Forge First Asset Management (2015 to 2017) | <p>Nil⁽⁶⁾</p> |
| <p>GINO DEMICHELE Calgary, Alberta</p> | <p>Nominee</p> | <ul style="list-style-type: none"> • President and Chief Executive Officer of A2 Capital Management Inc., a private merchant banking and trading operation since April 2006 • Chairman of Hilo Mining Ltd, a company listed on the TSXV (Feb 2022 to present) • Director of GR Silver Mining Ltd., a company listed on the TSXV (2014 to present) • President, Chief Executive Officer and Director Field Trip Health Ltd. | <p>2,350,400⁽⁷⁾</p> |

| Name, Province/State and Country of Residence and Present Offices Held | Director Since | Principal Occupation | Number of Common Shares ⁽¹⁾ |
|--|----------------|---|--|
| | | (formerly Newton Energy Corporation) a company listed on the TSXV (2017 to 2020) <ul style="list-style-type: none"> • Chief Executive Officer and Director of Greenhawk Resources Inc. (formerly Vogogo Inc.), a company listed on the TSXV (2016 to 2019) • President, Chief Executive Officer, Chief Financial Officer, Secretary, and Director of Medicenna Therapeutics Corp (formerly A2 Acquisition Corp.) (2015 to 2017) | |

Notes:

- (1) Information furnished by the respective director nominees.
- (2) Denotes a member of the Audit Committee.
- (3) Denotes a member of the Governance and Compensation Committee.
- (4) Does not include 50,000 Restricted Share Units to acquire Common Shares, and 80,000 Options to acquire Common Shares.
- (5) Does not include 60,000 Options to acquire Common Shares.
- (6) Does not include 80,000 Options to acquire Common Shares.
- (7) Does not include 60,000 Options to acquire Common Shares.

No proposed director is being elected under any arrangement or understanding between the proposed director and any other person or company.

Management recommends the approval of each of the nominees listed above for election as directors of the Company for the ensuing year.

Director and Nominee Biographies:

Kevin Taylor | *Director and Chairman of the Board*

Mr. Kevin Taylor is Chair of the Board of the Company. He is a seasoned executive with over 30 years of operating experience in Fortune 500 companies throughout North and South America. Mr. Taylor is currently the President and Chief Executive Officer of Prism Equity Group, as well as, TEREI International Limited, and was previously the President and General Manager of the carrier business of Nortel Networks Corporation in the Caribbean and Latin American region responsible for \$2B+ in revenue and 2000+ employees. Mr. Taylor graduated from Harvard Business School TGMP and received a Bachelor of Engineering - Science from the University of Western Ontario. Mr. Taylor acts as a director on a select number of public companies.

Daniel Gallucci | *Director and Chief Innovation Officer*

Mr. Gallucci has been the Chief Innovation Officer of the Company since December 14, 2020. Mr. Gallucci was the founder and acts as Director of Rehabilitation and Performance for Flux Bionetworks from 2014 to present. Mr. Gallucci was the founder of DG2, a data driven rehabilitation company, from 2013 to present. He has a Bachelor in Exercise Science and a minor in Psychology from the University of Connecticut and a Diploma Osteopath Manual Practitioner (DOMP) from Sutherland Academy of Osteopathy. Additionally, he completed a clinical neuroscience program with specialities in Neurologic Performance, Traumatic Brain Injury, Vestibular Rehabilitation, Neurodevelopmental Rehabilitation and Neurochemistry from Carrick Institute of Graduate Studies.

Sheetal Jaitly | *Director*

Mr. Jaitly is the founder and Chief Executive Officer of TribalScale, a software design and development company. Mr. Jaitly has broad management experience as the Chief Executive Officer of TribalScale (including with respect to financial statement matters) and is an avid investor in the technology space. He has been working in the tech sector for over 15 years. Mr. Jaitly was also a Director at Xtreme Labs from August 2010 until August 2015. Additionally, he is a Board Member for the Ontario Association of Food Banks and participates as a mentor at the Founder Institute and the DMZ at Ryerson University.

Andrew Parks | *Director*

Mr. Parks is the current Chief Executive Officer and Director of Fountain Asset Corporation, a TSXV listed investment issuer. He was previously a Portfolio Manager and Research Analyst/Trader for Forge First Asset Management. He is a Chartered Financial Analyst from the CFA Institute. He graduated from Wilfred Laurier University with an Honours Bachelor of Business Administration.

Gino DeMichele | *Director Nominee*

Mr. DeMichele currently serves as the President and Chief Executive Officer of A2 Capital Management Inc., a private merchant banking and trading operation active since 2006. Prior to this, Mr. DeMichele was Vice President and Senior Investment Advisor at Various Canadian brokerage firms from 1994 to 2013. He has been engaged in global financial markets since 1990 and brings 30 years of corporate finance, public -private equity and merger-and acquisition expertise. Mr. DeMichele is a co-founder of Nurosene and GR Silver Mining Ltd.

Cease Trade Orders

Except as disclosed below, no proposed director is, as at the date of this Information Circular, or has been, within ten years before the date of this Information Circular, a director, chief executive officer or chief financial officer of any company (including the Company) that:

- (a) was subject to a cease trade or similar order that was issued while the proposed director was acting in the capacity as director, chief executive officer or chief financial officer; or
- (b) was subject to a cease trade or similar order that was issued after the proposed director ceased to be a director, chief executive officer or chief financial officer and which resulted from an event that occurred while that person was acting in the capacity as director, chief executive officer or chief financial officer.

For the purposes hereof, the term “order” means:

- (c) a cease trade order;
- (d) an order similar to a cease trade order; or
- (e) an order that denied the relevant company access to any exemption under securities legislation, that was in effect for a period of more than thirty consecutive days.

Andrew Parks was a director of Braingrid Limited when it was subject to a cease trade order during 2020 due to failure to file certain continuous disclosure documents. Braingrid Limited (now named Tony G Co-Investment Holdings Ltd.) was reinstated for trading effective October 27, 2020.

Penalties and Sanctions

No proposed director of the Company has been subject to any penalties or sanctions imposed by a court relating to securities legislation or by a securities regulatory authority or has entered into a settlement agreement with a

securities regulatory authority, or has been subject to any other penalties or sanctions imposed by a court or regulatory body that would likely be considered important to a reasonable investor in deciding whether to vote for a proposed director.

Personal Bankruptcies

Except as disclosed below, no proposed director of the Company:

- (f) is, as at the date of this Information Circular, or has been within the ten years before the date hereof, a director or executive officer of any company (including the Company), that, while that person was acting in that capacity, or within a year of that person ceasing to act in that capacity, became bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency or was subject to or instituted any proceedings, arrangement or compromise with creditors or had a receiver, receiver manager or trustee appointed to hold its assets; or
- (g) has, within the ten years before the date of this Information Circular, become bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency, or became subject to or instituted any proceedings, arrangement or compromise with creditors, or had a receiver, receiver manager or trustee appointed to hold the assets of the director, executive officer or shareholder.

Sheetal Jaitly is the Chief Executive Officer of TribalScale Inc. (“TribalScale”), which, on May 19, 2020, filed a Notice of Intention to Make a Proposal under the Bankruptcy and Insolvency Act. MNP Ltd. was appointed as Trustee in the proposal. On, July 31, 2020, TribalScale’s proposal proceedings were continued under the Companies’ Creditors Arrangement Act (“CCAA”). TribalScale exited CCAA protection on January 28, 2021 after successfully restructuring its balance sheet and there are no further proceedings as against TribalScale.

IV. Appointment of Auditor

The Board recommends on the advice of the Audit Committee, that MNP LLP be reappointed as auditor of the Company at a remuneration to be fixed by the Board. MNP LLP, 11 Richmond St W #300, Toronto, Ontario M5H 2G4, was appointed as auditor of the Company, to hold office until the next annual general meeting. MNP LLP was first appointed as the Company’s auditor on February 13, 2021.

It is the intention of the persons named in the enclosed form of proxy, if not expressly directed to the contrary in such form of proxy, to vote such proxies FOR the appointment of MNP LLP as auditor of the Company.

AUDIT COMMITTEE AND RELATIONSHIP WITH AUDITOR

Pursuant to the provisions of section 224 of the *Business Corporations Act* (British Columbia) (the “**BCBCA**”), the Company is required to have an Audit Committee comprised of at least three directors, the majority of whom must not be officers or employees of the Company.

National Instrument 52-110 - *Audit Committees* of the Canadian Securities Administrators (“**NI 52-110**”) requires the Company, as a venture issuer, to disclose annually in its information circular certain information concerning the constitution of its audit committee and its relationship with its independent auditor, as set forth in the following:

The Audit Committee Charter

On April 19, 2021, the Board adopted the Audit Committee Charter. The Audit Committee Charter is attached to this Information Circular as Schedule “A”.

Composition of the Audit Committee

| Name of Member | Independent ⁽¹⁾ | Financially Literate ⁽²⁾ |
|-------------------------------|----------------------------|-------------------------------------|
| Andrew Parks ⁽³⁾ | Yes | Yes |
| Kevin Taylor | Yes | Yes |
| Sheetal Jaitly ⁽⁴⁾ | No | Yes |

Notes:

- (1) A member of the audit committee is independent if he or she has no direct or indirect 'material relationship' with the Company. A material relationship is a relationship which could, in the view of the Company's Board of Directors, reasonably interfere with the exercise of a member's independent judgment. An executive officer of the Company, such as the President or Secretary, is deemed to have a material relationship with the Company.
- (2) A member of the audit committee is financially literate if he or she has the ability to read and understand a set of financial statements that present a breadth and level of complexity of accounting issues that are generally comparable to the breadth and complexity of the issues that can reasonably be expected to be raised by the Company's financial statements.
- (3) Denotes Audit Committee Chair.
- (4) After the resignation of Kirstine Stewart on February 4, 2022, the Company appointed Sheetal Jaitly as the third member of its Audit Committee.

Relevant Education and Experience

In addition to each member's general business experience, the relevant education and experience of each Audit Committee member is set out under "*Director and Nominee Biographies*:".

Audit Committee Oversight

The Audit Committee will, among other things, make recommendations to the Board to nominate or compensate an external auditor.

Mandate and Responsibilities of the Audit Committee

The Audit Committee's mandate and responsibilities are detailed in its Charter, and include assisting the Board with fulfilling its responsibilities of oversight and supervision of the accounting and financial reporting practices and procedures on behalf of the Company and its direct and indirect subsidiaries, the adequacy of internal accounting controls and procedures, and the quality and integrity of the financial statements of the Company. In addition, the Audit Committee is responsible for overseeing the audits of the financial statements of the Company, for directing the auditors' examination of specific areas, for the selection of the independent external auditors of the Company and for the approval of all non-audit services for which the auditors of the Company may be engaged.

Reliance on Certain Exemptions

At no time since the commencement of the Company's most recently completed financial year has the Company relied on the exemption in Section 2.4 of NI 52-110 (*De Minimis Non-audit Services*), or an exemption from NI 52-110, in whole or in part, granted under Part 8 of NI 52-110.

The Company will rely on the exemptions provided for "venture issuers" in section 6.1 of NI 52-110 with respect to Part 3 – Composition of the Audit Committee and Part 5 – Reporting Obligations.

External Auditor Service Fees

The following table sets forth the "audit fees," "audit-related fees," "tax fees," and "other fees" billed during the financial years ended September 30, 2021 and September 30, 2020:

| Financial Year | Audit Fees | Audit-Related Fees | Tax Fees | All other fees |
|--------------------|------------|--------------------|----------|----------------|
| September 30, 2021 | \$45,500 | \$13,000 | - | - |
| September 30, 2020 | \$45,000 | - | \$10,000 | - |

Notes:

1. "Audit Fees" include fees necessary to perform the annual audit and quarterly reviews of the Company's consolidated financial statements and fees for review of tax provisions and for accounting consultations on matters reflected in the financial statements. Audit Fees also include audit or other attest services required by legislation or regulation, such as comfort letters, consents, reviews of securities filings and statutory audits.
2. "Audit-Related Fees" include services that are traditionally performed by the auditor. These audit-related services include employee benefit audits, due diligence assistance, accounting consultations on proposed transactions, internal control reviews and audit or attest services not required by legislation or regulation.
3. "Tax Fees" include fees for all tax services other than those included in "Audit Fees" and "Audit-Related Fees". This category includes fees for tax compliance, tax planning and tax advice. Tax planning and tax advice includes assistance with Nature of Services tax audits and appeals, tax advice related to mergers and acquisitions, and requests for rulings or technical advice from tax authorities.
4. "All Other Fees" include all other non-audit services.

STATEMENT OF CORPORATE GOVERNANCE

Corporate Governance

On June 30, 2005, the Canadian Securities Administrators enacted National Policy 58-201 – *Corporate Governance Guidelines* (the "**Governance Policy**") and National Instrument 58-101 – *Disclosure of Corporate Governance Practices* ("**NI 58-101**"). The Governance Policy provides guidelines on corporate governance practices while NI 58-101 requires Canadian reporting companies that are venture issuers to disclose their corporate governance practices in accordance with the disclosure items set out in Form 58-101F2.

The Company has reviewed its own corporate governance practices in light of the guidelines contained in the Governance Policy. The Company's practices comply generally with the guidelines, however, the current directors of the Company consider that some of the guidelines are not suitable for the Company at its current state of development and, therefore, the Company's governance practices do not reflect these particular guidelines. Given that the Company is relatively small in terms of both activities and market capitalization, the directors of the Company believe that the current governance structure is cost-effective and appropriate for the needs of the Shareholders.

Set out below is a description of the Company's corporate governance practices as required to be disclosed by NI 58-101.

Board of Directors

The Board is currently composed of four directors, two of whom (Andrew Parks and Kevin Taylor) are independent. The other remaining directors are Sheetal Jaitly and Daniel Gallucci, Chief Innovation Officer of the Company. Although Sheetal Jaitly is not an officer of the Company or an affiliate, he may not be determined to be independent as a result of the fees paid to TribalScale during the past three (3) year period, of which Mr. Jaitly is the Chief Executive Officer.

Directors are expected to attend Board meetings and meetings of committees on which they serve and to spend the time needed and meet as frequently as necessary to properly discharge their responsibilities.

Board Mandate

The Board facilitates independent supervision of management through meetings of the Board and through frequent informal discussions among independent members of the Board and management. In addition, the Board has access to the Company's external auditors, legal counsel and to any of the Company's officers.

The Board has a stewardship responsibility to supervise the management of and oversee the conduct of the business of the Company, provide leadership and direction to management, evaluate management, set policies appropriate for the business of the Company and approve corporate strategies and goals.

The day-to-day management of the business and affairs of the Company is delegated by the Board to the senior officers of the Company. The Board will give direction and guidance through the Chief Executive Officer to management and will keep management informed of its evaluation of the senior officers in achieving and complying with goals and policies established by the Board.

The Board recommends nominees to the Shareholders for election as directors, and immediately following each annual general meeting appoints an Audit Committee.

The Board exercises its independent supervision over management by its policies that require: (i) periodic meetings of the Board be held to obtain an update on significant corporate activities and plans; and (ii) all material transactions of the Company are subject to prior approval of the Board. To facilitate open and candid discussion among its independent directors, such directors are encouraged to communicate with each other directly to discuss ongoing issues pertaining to the Company.

Position Description

Because the Board is a small, working board, it has not yet developed written position descriptions and does not have a process for assessing the performance of the directors or the chair of the Board committees.

George Achilleos, the Chief Executive Officer and President of the Company is responsible for the general management of the day-to-day affairs of the Company within the guidelines established by the Board, consistent with decisions requiring prior approval of the Board.

Other Reporting Issuer Experience

The following directors, officers and promoters of the Company are, or have been within the last five years, directors, officers or promoters of other issuers that are or were reporting issuers in any Canadian jurisdiction:

| Name of Director | Name of Other Reporting Issuer |
|-------------------------|--|
| Andrew Parks | Tony G Co-Investment Holdings Ltd. (CSE) Fountain Asset Corp. (TSXV) Prominex Resource Corp. (unlisted) Global Health Clinics Ltd. (CSE) |
| Kevin Taylor | BC Craft Supply Co. Ltd. (formerly Pasha Brands Ltd.) (CSE) Field Trip Health Ltd. (TSX) Goodfood Market Corp. (TSX) Orion Nutraceuticals Inc. (CSE) SOL Global Investments Corp. (formerly Scythian Biosciences Corp.) (CSE) |
| Gino DeMichele | Hilo Mining Ltd. (TSXV) GR Silver Mining Ltd. (TSXV) Field Trip Health Ltd. (formerly Newton Energy Corporation (TSXV) Greenhawk Resources Inc. (formerly Vogogo Inc.) (TSXV) Medicenna Therapeutics Corp. (formerly A2 Acquisition Corp. (TSXV) |

Orientation and Continuing Education

If and when new directors are appointed to the Board they will receive orientation, commensurate with their previous experience, on the Company's business, assets and industry and on the responsibilities of directors. Meetings of the Board are sometimes held at the Company's offices and, from time to time, are combined with presentations by the Company's management to give the directors additional insight into the Company's business. In addition, management of the Company makes itself available for discussion with all members of the Board.

Ethical Business Conduct

The Company has adopted a code of ethics and business conduct policy (the "Code") which provides a general statement of the Company's expectations regarding the ethical standards that each director, officer and employee should adhere to while acting on behalf of the Company. Each director, officer and employee is expected to read and

become familiar with the ethical standards described in this Code and may be required, from time to time, to affirm his or her agreement to adhere to such standards.

The Code endorses the following principles: (a) honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional relationships; (b) full, fair, accurate, timely and understandable disclosure; (c) compliance with applicable governmental laws, rules and regulations; and (d) accountability by all directors, officers and employees to adhere to the policy. The Code addresses bribery and corruption, conflicts of interest and corporate opportunities, insider trading, protection of confidential information, fair dealing, related party transactions, discrimination and harassment, health and safety, accurate record keeping, and political contributions.

Nomination of Directors

The Board has not formed a nominating committee or similar committee to assist the Board with the nomination of directors for the Company. The Board considers itself too small to warrant creation of such a committee, and the Board believes that they have sufficient contacts which they can draw upon to identify new members of the Board as needed from time to time.

The Board will continually assess its size, structure and composition, taking into consideration its current strengths, skills and experience, proposed retirements and the requirements and strategic direction of the Company. As required, the members of the Board will recommend suitable candidates for consideration as new members of the Board.

Compensation

The Governance and Compensation Committee was recently established by the Board in January 2022. It is composed entirely of directors that are not part of management. The members of the Governance and Compensation Committee are Kevin Taylor (Chair) and Sheetal Jaitly. The Governance and Compensation Committee is responsible for the development and supervision of the Company's approach to compensation for directors, officers, and senior management as well as bonuses and any increases in compensation to employees or staff that would have a material impact on the Company's expenses. Its mandate includes conducting reviews with regard to directors' and officers' compensation at least once a year. For information regarding the steps taken to determine compensation for the directors and the executive officers, see disclosure under heading "*Statement of Executive Compensation*".

Assessments

The Board has not implemented a process for assessing its effectiveness. As a result of the Company's small size and the Company's stage of development, the Board considers a formal assessment process to be inappropriate at this time. The Board plans to continue evaluating its own effectiveness on an ad hoc basis.

The Board does not formally assess the performance or contribution of individual members of the Board or of any of the Company's committees.

STATEMENT OF EXECUTIVE COMPENSATION

For the purpose of this Information Circular:

“**CEO**” means each individual who acted as Chief Executive Officer of the Company or acted in a similar capacity for any part of the most recently completed financial year;

“**CFO**” means each individual who acted as Chief Financial Officer of the Company or acted in a similar capacity for any part of the most recently completed financial year; and

“**Named Executive Officer**” or “**NEO**” means: (i) a CEO; (ii) a CFO; (iii) the most highly compensated executive officer, including any of the Company's subsidiaries, or individuals acting in a similar capacity, other than the CEO and CFO, at the end of the most recently completed financial year whose total compensation was more than \$150,000

as determined in accordance with subsection 1.3(5) of Form 51-102F6V - *Statement of Executive Compensation Venture Issuers*, for that financial year; and (iv) each individual who would be a NEO under paragraph (iii) but for the fact that the individual was neither an executive officer of the Company, nor acting in a similar capacity at the end of the most recently completed financial year.

During the year ended September 30, 2021, the Company had two NEOs, namely: (i) Ranjit Bath, the CEO of the Company; and (ii) Blake Sing, the CFO of the Company.

Compensation Discussion & Analysis

The purpose of this Compensation Discussion and Analysis is to provide information about the Company's executive compensation objectives and processes and to discuss compensation decisions relating to its NEOs listed in the Summary Compensation Table set out below.

The Board assumes responsibility for reviewing and monitoring the long-range compensation strategy for the senior management of the Company. In determining executive compensation, the Board considers the Company's financial circumstances at the time decisions are made regarding executive compensation, and also the anticipated financial situation of the Company in the mid and long-term.

The Governance and Compensation Committee is responsible for the development and supervision of the Company's approach to compensation for directors, officers, and senior management as well as bonuses and any increases in compensation to employees or staff that would have a material impact on the Company's expenses.

Compensation Objectives and Principles

The compensation program for the senior management of the Company is designed to ensure that the level and form of compensation achieves certain objectives, including:

- (i) attracting and retaining qualified executives;
- (ii) motivating the short and long-term performance of these executives; and
- (iii) better aligning their interests with those of the Company's shareholders.

In compensating its senior management, the Company has employed a combination of base salary or consulting fees, bonus compensation and equity participation through its Stock Option Plan (as defined below) and Equity Incentive Plan (as defined below). The Company does not provide any retirement benefits for its directors or officers.

Elements of Compensation

In the Board's view, paying base salaries or consulting fees which are reasonable in relation to the level of service expected while remaining competitive in the markets in which the Company operates is a first step to attracting and retaining qualified and effective executives. Competitive salary information on comparable companies within the Company's industry is compiled from a variety of sources, including national and international publications.

The Board will consider executive bonus compensation dependent upon the Company meeting its strategic objectives and milestones and sufficient cash resources being available for the granting of bonuses.

The Company believes that encouraging its executives and employees to become shareholders is the best way of aligning their interests with those of its shareholders. Equity participation is accomplished through the Company's Stock Option Plan and Equity Incentive Plan. Options, RSUs and DSUs may be granted to executives and employees taking into account a number of factors, including the amount and term of securities based compensation previously granted, base salary or consulting fees and bonuses and competitive factors. The amounts and terms of options, RSUs and DSUs granted are determined by the Board.

The compensation of the Company's NEOs is determined by the Company's Board of Directors.

The Board compensation program is designed to provide competitive levels of compensation, a significant portion of which is dependent upon individual and corporate performance and contribution to increasing shareholder value. The Board recognizes the need to provide a total compensation package that will attract and retain qualified and experienced executives as well as align the compensation level of each executive to that executive's level of responsibility. In general, a NEO's compensation is comprised of a salary / consulting fee, annual bonuses, stock option grants, and RSU grants. The objectives and reasons for this system of compensation are generally to allow the Company to remain competitive compared to its peers in attracting and retaining experienced personnel.

The Governance and Compensation Committee has not established a formal set of benchmarks or performance criteria to be met by NEOs, rather, the members of the Governance and Compensation Committee use their own assessments of the success (or otherwise) of the Company, both absolutely or in relation to companies they consider to be its peers, to determine, collectively, whether or not the executive officers are successfully achieving the Company business plan and strategy and whether they have over, or under, performed in that regard. The Governance and Compensation Committee has not established any set or formal formula for determining executive officer compensation, either as to the amount thereof or the specific mix of compensation elements.

The Governance and Compensation Committee has the authority to engage and compensate, at the expense of the Company, any outside advisor that it determines to be necessary to permit it to carry out its duties (including compensation consultants and advisers), but it did not retain any such outside consultants or advisers during the financial year ended September 30, 2021.

Stock option and RSU grants are designed to reward the NEOs for success on a similar basis as the shareholders of the Company, but these rewards are highly dependent upon the volatile stock market, much of which is beyond the control of the NEOs.

Compensation Governance

In establishing compensation for executive officers, the Board as a whole seeks to accomplish the following goals:

- (iv) To recruit and subsequently retain highly qualified executive officers by offering competitive compensation and benefits;
- (v) To motivate executives to achieve important corporate and personal performance objectives and reward them when such objectives are met; and
- (vi) To align the interests of executive officers with the long-term interests of shareholders through participation in the Stock Option Plan.

When considering the appropriate executive compensation to be paid to our officers, the Board have regard to a number of factors including: (i) recruiting and retaining executives critical to the success of the Company and the enhancement of Shareholder value; (ii) providing fair and competitive compensation; (iii) balancing the interests of management and the Shareholders; (iv) rewarding performance, both on an individual basis and with respect to operations generally; and (v) available financial resources.

Compensation Risks

Neither the Board nor the Governance and Compensation Committee has proceeded to a formal evaluation of the implications of the risks associated with the Company's compensation policies and practices. The Board will continually review the Company's compensation policies to identify any practice that might encourage an employee to expose the Company to unacceptable risk. Risk management is a consideration of the Board when implementing its compensation program, and the Board and the Governance and Compensation Committee does not believe that the Company's compensation program results in unnecessary or inappropriate risk taking including risks that are likely to have a material adverse effect on the Company. The Board takes a conservative approach to executive compensation

rewarding individuals for the success of the Company once that success has been demonstrated and incenting them to continue that success through the grant of long-term incentive awards.

Long-Term Incentive-Based Awards

Long-term incentives in the form of stock options, restricted share units and deferred share units are intended to align the interests of the Company's directors and executive officers with those of the Company's Shareholders and to provide a long-term incentive to reward those individuals for their contribution to the generation of shareholder value, while reducing the burden of cash compensation that would otherwise be payable by the Company.

For a detailed discussion of the Stock Option Plan and Equity Incentive Plan please see disclosure under "*Stock Option Plan*" and "*Equity Incentive Plan*".

Director and Named Executive Officer Compensation, Excluding Compensation Securities

Other than as disclosed in this Information Circular, the only arrangements the Company has, standard or otherwise, pursuant to which the Company compensated directors for their services in their capacity as directors, or for committee participation, involvement in special assignments or for services as a consultant or expert during the most recently completed financial year or subsequently, are by: (i) the issuance of incentive stock options or RSUs; and (ii) reimbursement for out-of-pocket expenses incurred on behalf of the Company.

The compensation paid to the NEOs and directors during the Company's two most recently completed financial years ended September 30, 2021 and 2020, excluding compensation securities, is as set out below:

Table of Compensation excluding Compensation Securities

| Name and position | Year | Salary, consulting fee, retainer or commission (\$) | Bonus (\$) | Committee or meeting fees (\$) | Value of perquisites (\$) | Value of all other compensation (\$) | Total compensation (\$) |
|--|------|---|------------|--------------------------------|---------------------------|--------------------------------------|-------------------------|
| Ranjit Bath, <i>Former CEO and Director</i> ⁽¹⁾ | 2021 | 249,496 | Nil | Nil | Nil | Nil | 249,496 |
| | 2020 | Nil | Nil | Nil | Nil | Nil | Nil |
| George Achilleos <i>President and CEO</i> ⁽⁸⁾ | 2021 | 34,935 | Nil | Nil | Nil | Nil | 34,935 |
| | 2020 | Nil | Nil | Nil | Nil | Nil | Nil |
| Blake Sing, <i>Chief Financial Officer and Corporate Secretary</i> ⁽²⁾ | 2021 | 59,583 | Nil | Nil | Nil | Nil | 59,583 |
| | 2020 | Nil | Nil | Nil | Nil | Nil | Nil |
| Daniel Gallucci, | 2021 | 87,000 ⁽⁷⁾ | Nil | Nil | Nil | Nil | 87,000 |

| Name and position | Year | Salary, consulting fee, retainer or commission | Bonus | Committee or meeting fees | Value of perquisites | Value of all other compensation | Total compensation |
|---|------|--|-------|---------------------------|----------------------|---------------------------------|--------------------|
| <i>Chief Innovation Officer and Director</i> ⁽³⁾ | 2020 | Nil | Nil | Nil | Nil | Nil | Nil |
| Sheetal Jaitly, <i>Director</i> ⁽⁴⁾ | 2021 | Nil | Nil | Nil | Nil | Nil | Nil |
| | 2020 | Nil | Nil | Nil | Nil | Nil | Nil |
| Andrew Parks, <i>Director</i> ⁽⁵⁾ | 2021 | Nil | Nil | Nil | Nil | Nil | Nil |
| | 2020 | Nil | Nil | Nil | Nil | Nil | Nil |
| Kirstine Stewart <i>Director</i> ⁽⁶⁾ | 2021 | Nil | Nil | Nil | Nil | Nil | Nil |
| | 2020 | Nil | Nil | Nil | Nil | Nil | Nil |

Notes:

- (1) Appointed as CEO on December 14, 2020 and director on March 26, 2021. Ceased both roles on February 17, 2022.
- (2) Appointed as CFO and Corporate Secretary on February 1, 2021.
- (3) Appointed as Chief Innovation Officer and director on March 26, 2021.
- (4) Appointed as director on March 26, 2021.
- (5) Appointed as director on March 26, 2021.
- (6) Appointed as director on March 26, 2021. Resigned as director on February 4, 2021.
- (7) Amount represents fees paid to Mr. Gallucci from October 1, 2020 to September 30, 2021.
- (8) Appointed as Chief Operating Officer (COO) on August 25, 2021 and as CEO on February 17, 2022.

Stock Options and Other Compensation Securities

The following table sets forth information in respect of all compensation securities granted or issued to each director and NEO by the Company or one of its subsidiaries for services provided or to be provided, directly or indirectly to the Company or its subsidiaries in the Company's most recently completed financial year ended September 30, 2021.

| Compensation Securities | | | | | | | |
|--|-------------------------------|--|------------------------|-------------------------------------|---|--|---------------|
| Name and position | Type of compensation security | Number of compensation securities, number of underlying securities and percentage of class | Date of issue or grant | Issue, conversion or exercise price | Closing price of security or underlying security on date of grant | Closing price of security or underlying security at year end | Expiry date |
| Ranjit Bath, <i>CEO and Director</i> ⁽¹⁾⁽⁷⁾ | Stock Options | 200,000 | March 4, 2021 | \$0.40 | N/A | \$1.67 | March 4, 2026 |
| | Stock Options | 300,000 | June 8, 2021 | \$0.90 | \$0.90 | | June 8, 2026 |

| Compensation Securities | | | | | | | |
|--|-------------------------------|--|-------------------------------------|-------------------------------------|---|--|-------------------|
| Name and position | Type of compensation security | Number of compensation securities, number of underlying securities and percentage of class | Date of issue or grant | Issue, conversion or exercise price | Closing price of security or underlying security on date of grant | Closing price of security or underlying security at year end | Expiry date |
| George Achilleos <i>President and CEO</i> ⁽⁸⁾ | Stock Options | 75,000 | June 8, 2021 | \$0.90 | \$0.90 | \$1.67 | June 8, 2026 |
| | Stock Options | 125,000 | August 3, 2021 November 11, 2021 | \$2.15 | \$2.15 | | August 3, 2026 |
| | Stock Options | 300,000 | | \$1.79 | \$1.79 | | November 11, 2026 |
| Blake Sing, <i>Chief Financial Officer and Corporate Secretary</i> ⁽²⁾ | Stock Options | 150,000 | June 8, 2021 | \$0.90 | \$0.90 | \$1.67 | June 8, 2026 |
| Daniel Gallucci, <i>Chief Innovation Officer and Director</i> ⁽³⁾ | Common Shares | 1,717,000 | June 8, 2021 | \$0.90 | \$0.90 | \$1.67 | N/A |
| Sheetal Jaitly, <i>Director</i> ⁽⁴⁾ | Stock Options | 60,000 | June 8, 2021 | \$0.90 | \$0.90 | \$1.67 | June 8, 2026 |
| Andrew Parks, <i>Director</i> ⁽⁵⁾ | Stock Options | 80,000 | June 8, 2021 | \$0.90 | \$0.90 | \$1.67 | June 8, 2026 |
| Kirstine Stewart, <i>Director</i> ⁽⁶⁾⁽⁷⁾ | Stock Options | 60,000 | June 8, 2021 | \$0.90 | \$0.90 | \$1.67 | June 8, 2026 |

Notes:

- (1) Appointed as CEO on December 14, 2020 and director on March 26, 2021. Ceased both roles on February 17, 2022.
- (2) Appointed as CFO and Corporate Secretary on February 1, 2021.
- (3) Appointed as Chief Innovation Officer and director on March 26, 2021.
- (4) Appointed as director on March 26, 2021.
- (5) Appointed as director on March 26, 2021.
- (6) Appointed as director on March 26, 2021. Resigned as director on February 4, 2021.
- (7) All vested Options that remain unexercised will expire 30 days following cessation of employment and all Options not vested prior to cessation of employment are terminated pursuant to the terms of the Stock Option Plan.
- (8) Appointed as Chief Operating Officer (COO) on August 25, 2021 and as CEO on February 17, 2022

Exercise of Compensation Securities by Directors and NEOs

No director or NEO exercised compensation securities during the Company's most recently completed financial year ended September 30, 2021.

Stock Option Plan

The Stock Option Plan (the “**Stock Option Plan**”) was adopted by the Board effective September 1, 2020. The purpose of the Stock Option Plan is to advance the interests of the Company and its shareholders by attracting, retaining and motivating the performance of selected directors, officers, employees or consultants of the Company of high caliber and potential and to encourage and enable such persons to acquire and retain an interest in the Company by ownership of its Common Shares. The Stock Option Plan is a “rolling” stock option plan and provides that the aggregate number of securities reserved for issuance, set aside and made available for issuance under the Stock Option Plan may not exceed 10% of the issued and outstanding Common Shares of the Company at the time of granting of Options.

The number of Common Shares which may be reserved in any 12-month period for issuance to any one individual upon exercise of all options held by that individual may not exceed 5% of the issued and outstanding Common Shares at the time of the grant. The number of Common Shares which may be reserved in any 12-month period for issuance to any one consultant may not exceed 2% of the issued and outstanding Common Shares and the maximum number of Common Shares which may be reserved in any 12-month period for issuance to all persons engaged in investor relations activities may not exceed 2% of the issued and outstanding Common Shares. The Stock Option Plan provides that options granted to any person engaged in investor relations activities will vest in stages over not less than a 12 month period with no more than ¼ of the stock options vesting in any three-month period.

The Stock Option Plan will be administered by the Board or a special committee of directors, either of which will have full and final authority with respect to the granting of all stock options thereunder. Stock options may be granted under the Stock Option Plan to such directors, officers, employees or consultants of the Company, as the Board may from time to time designate.

The exercise price of any stock options granted under the Stock Option Plan shall be determined by the Board but may not be less than 100% of fair market value of the Common Shares on the date of grant as determined in good faith by the Board, provided that, because the Common Shares are listed on the CSE, the exercise price per option shall, subject to any other requirement of the CSE, be no lower than the greater of the closing market price of the Common Shares on the CSE on (a) the trading day prior to the date of grant of the stock options; and (b) the date of grant of the stock options.

The term of any options granted under the Stock Option Plan shall be determined by the Board at the time of grant, subject to earlier termination in accordance with the terms of the Stock Option Plan, provided that term of any stock options granted under the Stock Option Plan may not exceed the lesser of 10 years or the maximum term permitted by the CSE. Options granted under the Stock Option Plan are not to be transferable or assignable other than by will or other testamentary instrument or pursuant to the laws of succession. Subject to certain exceptions, in the event that an option holder ceases to hold a position with the Company or ceases to provide consulting or investor relations activities for or on behalf of the Company, as the case may be, all unvested options granted to such option holder will expire and terminate immediately and all vested options granted to such option holder will expire upon the earlier of (a) the expiry date of the options, and (b) the 30th day after the option holder ceases to hold a position with the Company or ceases to provide consulting or investor relations activities for or on behalf of the Company, as the case may be.

The Stock Option Plan was approved by the shareholders of the Company on March 26, 2021.

Equity Incentive Plan

The Equity Incentive Plan was adopted by the Board effective February 12, 2021. The Equity Incentive Plan provides flexibility to the Company to grant equity-based incentive awards in the form of restricted share units and deferred share units (as described in further detail below, and collectively referred to as “**Awards**”) to attract, retain and motivate qualified directors, officers, employees and consultants (collectively referred to as “**participants**”) of the Corporation.

The purpose of the Equity Incentive Plan is to, among other things: (i) provide the Company with a mechanism to attract, retain and motivate qualified directors, officers, employees and consultants of the Company; (ii) reward directors, officers, employees and consultants that have been granted Awards under the Equity Incentive Plan for their

contributions toward the long-term goals and success of the Company; and (iii) enable and encourage such directors, officers, employees and consultants to acquire Common Shares of the Company as long-term investments and proprietary interests in the Company.

The Equity Incentive Plan provides that the maximum number of Common Shares which may be reserved for issuance under the Equity Incentive Plan, together with any of the Company's other security based compensation arrangements ("**Security Based Compensation Arrangements**"), which currently includes stock options under the Plan, may not exceed 10% of the issued Common Shares.

The plan administrator of the Equity Incentive Plan (the "**Equity Incentive Plan Administrator**") will initially be the Board or a committee of the Board, if delegated. The Equity Incentive Plan Administrator will: determine which directors, officers, employees or consultants are eligible to receive Awards under the Equity Incentive Plan; determine any additional vesting provisions or other restrictions on Awards; determine conditions under which Awards may be granted, vested or settled, including establishing performance goals; establish the form of Award agreement ("**Award Agreement**"); cancel, amend or adjust Awards in compliance with the Equity Incentive Plan; and make all other determinations and take all other actions necessary or advisable for the implementation and administration of the Equity Incentive Plan. In addition, the Equity Incentive Plan Administrator will interpret the Equity Incentive Plan and may adopt administrative rules, regulations, procedures and guidelines governing the Equity Incentive Plan or any Awards granted under the Equity Incentive Plan as it deems to be appropriate. The Equity Incentive Plan Administrator may also from time to time, without notice and without approval of the holders of the Common Shares, amend, modify, change, suspend or terminate the Equity Incentive Plan or any Awards granted pursuant thereto as it, in its discretion, determines appropriate, provided that: (i) no such amendment, modification, change, suspension or termination of the Equity Incentive Plan or any Award granted pursuant thereto may, subject to termination for cause, materially impair any rights of a Participant or materially increase any obligations of a Participant under the Equity Incentive Plan without the consent of such Participant, unless the Equity Incentive Plan Administrator determines such adjustment is required or desirable in order to comply with any applicable securities laws or stock exchange requirements. Further, the Equity Incentive Plan Administrator may also from time to time, without notice and without approval of the holders of the Common Shares, make any such amendments to the Equity Incentive Plan as are required for compliance with the policies of the applicable exchange on which the Common Shares are listed and posted for trading. Notwithstanding the above, and subject to the rules of the CSE, the approval of shareholders is required to effect any of the following amendments to the Equity Incentive Plan: (a) increasing the number of Common Shares reserved for issuance under the Equity Incentive Plan, except pursuant to the provisions in the Equity Incentive Plan which permit the Equity Incentive Plan Administrator to make equitable adjustments in the event of transactions affecting the Corporation or its capital; (b) extending the term of Awards beyond the original expiry, subject to application of blackout policies; or (c) permitting Awards to be transferred to a person.

Awards of restricted share units ("**RSU**") and deferred share units ("**DSU**") may be made under the Equity Incentive Plan. All of the Awards are subject to the conditions, limitations, restrictions, exercise price, vesting, settlement and forfeiture provisions determined by the Equity Incentive Plan Administrator, in its sole discretion, subject to such limitations provided in the Equity Incentive Plan, and will generally be evidenced by an Award Agreement. In addition, subject to the limitations provided in the Equity Incentive Plan and in accordance with applicable law, the Equity Incentive Plan Administrator may accelerate or defer the vesting or payment of Awards, cancel or modify outstanding Awards, and waive any condition imposed with respect to Awards or Common Shares issued pursuant to Awards.

A RSU is a unit equivalent in value to a Common Share credited by means of a bookkeeping entry in the books of the Corporation which entitles the holder to receive one Common Share for each RSU. RSUs shall, unless otherwise determined by the Equity Incentive Plan Administrator, and as specifically set out in the Award Agreement, vest as to 1/3 on each of the first, second and third anniversaries of the date of grant. Upon settlement, which shall be within 60 days of vesting, and in any event no later than December 15 of the third year following the year in respect of which the RSU is granted, holders of RSUs will receive any or a combination of the following (as determined solely at the discretion of the Equity Incentive Plan Administrator): (i) one fully paid and non-assessable Common Share issued from treasury in respect of each vested RSU; (ii) one fully paid and non-assessable Common Share purchased by the Company on the open market by an independent broker designated by the Equity Incentive Plan Administrator in respect of each vested RSU; or (iii) a cash payment. Any cash payment is determined by multiplying the number of

RSUs redeemed for cash by the market value of a Common Share (calculated with reference to the five-day volume weighted average trading price) (the "**Market Price**") on the date of settlement.

A DSU is a unit equivalent in value to a Common Share credited by means of a bookkeeping entry in the books of the Corporation which entitles the holder to receive one Common Share for each DSU on a future date, which is no earlier than the termination of services of the Participant with the Corporation, and no later than one year after the termination of services of the Participant with the Corporation, subject to the discretion of the Equity Incentive Plan Administrator. DSUs shall, unless otherwise determined by the Equity Incentive Plan Administrator, and as specifically set out in the Award Agreement, vest as to 1/3 on each of the first, second and third anniversaries of the date of grant. In addition to grants made by the Equity Incentive Plan Administrator to all participants, DSUs allow for directors of the Corporation to elect that any portion of a director's fees may be payable in DSUs upon the election by such director. Upon settlement, holders of DSUs will receive any or a combination of the following (as determined solely at the discretion of the Equity Incentive Plan Administrator): (i) one fully paid and non-assessable Common Share issued from treasury in respect of each vested DSU; or (ii) a cash payment. Any cash payment is determined by multiplying the number of DSUs redeemed for cash by the Market Price of a Common Share on the date of settlement.

If a settlement date for an Award occurs during, or within nine business days after, a trading black-out period imposed by the Corporation to restrict trades in its securities, then, notwithstanding any other provision of the Equity Incentive Plan, unless the delayed expiration would result in tax penalties, the Award shall be settled no more than ten business days after the trading black-out period is lifted by the Corporation.

Although the Equity Incentive Plan does not stipulate a term for Awards granted thereunder, they must vest and settle in accordance with the provisions of the Equity Incentive Plan and any applicable Award Agreement, which Award Agreement may include an expiry date for a specific Award.

The following table describes the impact of certain events that may, unless otherwise determined by the Equity Incentive Plan Administrator or as set forth in an Award Agreement, lead to the early expiry of Awards granted under the Equity Incentive Plan:

| | |
|--|---|
| Termination for cause | Forfeiture of all unvested Awards. At the discretion of the Equity Incentive Plan Administrator, vested Awards may also be forfeited. |
| Voluntary resignation of a Participant | Forfeiture of all unvested Awards. |
| Termination other than for cause | Forfeiture of all unvested Awards. Settlement of all vested Awards in accordance with the Equity Incentive Plan. |
| Death or disability of a Participant | Acceleration of vesting of all unvested Awards. |

The Equity Incentive Plan was approved by the shareholders of the Company on March 26, 2021.

Pension Plan Benefits

The Company does not have any pension or retirement plan.

Employment, consulting and management agreements

Other than the executive contractor agreements described below, the Company does not have any other compensation agreements or arrangements in place with respect to services provided by a NEO or director.

The Company and Ranjit Bath entered into a contractor agreement dated December 4, 2020 (the "Bath Contractor Agreement"). The Bath Contractor Agreement has a two (2) year term. Pursuant to the terms of the Bath Contractor Agreement, Mr. Bath will serve as CEO of the Company, will undertake the duties and exercise the powers of that office and shall perform and assume such other reasonable additional duties and responsibilities as the Board may require and assign from time to time. As compensation for the performance of such duties, the Company paid Mr. Bath a base annual salary of USD\$250,000 in equal monthly installments. Mr. Bath is also eligible for discretionary

cash milestone payments in amounts to be determined by the Board. In addition, under the terms of the Bath Contractor Agreement, Mr. Bath is entitled the following Option grants: (a) 200,000 Options at an exercise price of \$0.40 upon signing of the Bath Contractor Agreement, (b) 300,000 Options at an exercise price of \$0.90 on June 8, 2021; and (c) 500,000 Options at an exercise price equal to the then current market price upon the earlier of the closing of the Company's first financing following the initial public offering or the closing of a transfer, purchase, assignment, amalgamation, merger, combination, consolidation, arrangement or other reorganization involving the Company.

Under the Bath Contractor Agreement, the Company may terminate the agreement immediately upon material breach by Mr. Bath and at any time, without advance notice, upon payment of the following amounts to Mr. Bath:

- a) any earned and unpaid monthly fees; and
- b) all reasonable expenses incurred by Mr. Bath prior to the termination date but not yet reimbursed; and
- c) in respect of: (i) termination which occurs from the period following the expiration of Probation Period (defined as 90 days following December 4, 2020) until the last day of year one of the agreement, a lump sum equal to six (6) months of the annual fees then payable to Mr. Bath; (ii) termination which occurs during year two of the agreement, a lump sum equal to twelve (12) months of the annual fees then payable to Mr. Bath.

The Company and Mr. Bath have entered into a separation agreement (the "Separation Agreement") dated February 17, 2022, in connection with the end of Mr. Bath's engagement as CEO of the Company. Pursuant to the terms of the Separation Agreement, the Company paid Mr. Bath a one-time lump sum payment of USD\$250,000. In addition, one-third (1/3) of the Options granted to Mr. Bath pursuant to an option agreement effective March 4, 2021, which Options were to vest on March 4, 2022, shall be considered vested as of February 17, 2022.

The Company and Blake Sing entered into a contractor agreement dated February 1, 2021 (the "Sing Contractor Agreement"). The Sing Contractor Agreement provides for a three-year term beginning February 1, 2021. Pursuant to the terms of the Sing Contractor Agreement, Mr. Sing will serve as CFO of the Company, will undertake the duties and exercise the powers of that office including but not limited to overseeing all finance functions of the organization and assisting with strategy and operations from time to time as required. As compensation for the performance of such duties, the Company shall pay Mr. Sing a base annual salary of \$130,000 in equal monthly installments. Mr. Sing is also eligible to receive up to 30% of his annual salary in cash incentives based on performance metrics to be determined by the Board. Mr. Sing is entitled to reimbursement for personal health insurance of up to \$200 per month and all reasonable expenses incurred in connection with the Company's business, in accordance with the Company's applicable policies and subject to written approval by the Company. In addition, Mr. Sing is entitled to a grant of 150,000 Options at any exercise price of \$0.90 on June 8, 2021 to vest over a period of three years with 1/3 of the Options vesting on each anniversary date from the later of (a) date of grant; and (b) the completion of the Probation Period (as defined in the Sing Contractor Agreement).

SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS

The following table sets out equity compensation plan information as at the Company's September 30, 2021 financial year end.

| | Number of securities to be issued upon exercise of outstanding options, warrants, and rights | Weighted-average exercise price of outstanding options, warrants and rights | Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) |
|--|---|--|--|
| Plan Category | (a) | (b) | (c) |
| Equity compensation plans approved by shareholders | 2,727,666 | \$1.44 | 1,300,583 |

| | | | |
|--|-----------|--------|-----------|
| Equity compensation plans not approved by shareholders | N/A | N/A | N/A |
| Total | 2,727,666 | \$1.44 | 1,300,583 |

INDEBTEDNESS OF DIRECTORS AND EXECUTIVE OFFICERS

At no time during the last completed financial year was any current director, executive officer or employee or any former director, executive officer or employee of the Company, or any proposed nominee for election as a director of the Company:

- (h) indebted to the Company; or
- (i) indebted to another entity where such indebtedness is the subject of a guarantee, support agreement, letter of credit or other similar arrangement or understanding provided by the Company

INTEREST OF INFORMED PERSONS IN MATERIAL TRANSACTIONS

Except as otherwise disclosed herein, no informed person of the Company, proposed director of the Company or any associate or affiliate of an informed person or proposed director, has any material interest, direct or indirect, in any transaction since the commencement of the Company’s financial year ended September 30, 2021, or in any proposed transaction which has materially affected or would materially affect the Company or any of its subsidiaries.

The term “informed person” as defined in National Instrument 51-102 - *Continuous Disclosure Obligations* means a director or executive officer of the Company, or any person or company who beneficially owns, directly or indirectly, voting securities of the Company or who exercises control or direction over voting securities of the Company carrying more than 10% of the voting rights attached to all outstanding voting securities of the Company, other than voting securities held by the person or company as underwriter in the course of a distribution.

Sheetal Jaitly, a director of the Company, is the Chief Executive Officer of TribalScale. On October 7, 2020, the Company engaged TribalScale to provide design, engineering, quality assurance and product management support for the Company's Mobile Application pursuant to the terms of a statement of work dated October 7, 2020, as amended pursuant to the amending agreement dated February 17, 2021 (“TribalScale SOW”) and a master services agreement dated October 21, 2020 (“TribalScale MSA”). Pursuant to the terms of the TribalScale SOW, the Company issued to TribalScale a total of 493,827 Common Shares on June 8, 2021 at a deemed price of \$0.81 per Common Share. 123,456 of the 493,827 Common Shares issued to TribalScale are subject to a 12 month contractual expiring on June 8, 2022.

Chief Science Officer, Dr. Joseph Geraci, is the founder and former CEO of NetraMark Corp. On October 14, 2021, the Company acquired NetraMark Corp. pursuant to the terms of a share exchange agreement dated October 8, 2021 (the “Share Exchange Agreement”). Pursuant to the terms of the Share Exchange Agreement, Nurosene acquired all of the issued and outstanding securities of NetraMark for a purchase price of CAD\$15,000,000 payable as follows to shareholders of NetraMark: (i) 6,148,325 Common Shares at a price of approximately \$2.09 (“Purchase Shares”), representing an amount of CAD\$12,850,000 and (ii) CAD\$2,150,000 in cash. The Purchase Shares are subject to a contractual escrow ranging from 12 to 36 months. As part of the transaction, Dr. Geraci received 4,33,954 Common Shares of Nurosene, subject to contractual escrow over 36 months.

MANAGEMENT CONTRACTS

There are no management functions of the Company, which are to any substantial degree performed by a person or company other than the directors or executive officers of the Company.

ADDITIONAL INFORMATION

Additional information relating to the Company is on SEDAR at www.sedar.com under “Company Profiles – Nurosene Health Inc.”. The Company’s audited consolidated financial statements and management discussion and analysis (“**MD&A**”) for the period ended September 30, 2021 are available for review under the Company’s profile on SEDAR. Shareholders may contact the Company to request copies of the financial statements and MD&A by: (i) email to Blake Sing at blake@nurosene.com or (ii) telephone to +1 (416) 859-8838.

OTHER MATTERS

Management knows of no other matters to come before the Meeting, other than those referred to in the Notice of Meeting accompanying this Information Circular. However, if any other matters shall properly come before said Meeting, it is the intention of the persons designated by management of the Company in the form of Proxy accompanying this Information Circular to vote the same in accordance with their best judgment of such matters.

APPROVAL OF INFORMATION CIRCULAR

The contents of this Information Circular have been approved and its mailing authorized by the directors of the Company.

DATED at Toronto, Ontario, the 3rd day of March, 2022.


**ON BEHALF OF THE BOARD OF NUROSENE
HEALTH INC.**

“Kevin Taylor”

Kevin Taylor
Chairman of the Board

SCHEDULE "A"

AUDIT COMMITTEE CHARTER
(see attached)



AUDIT COMMITTEE CHARTER

MAY 21, 2021

NUROSENE HEALTH INC.**1. Role and Objective**

The Audit Committee (the “**Committee**”) is a committee of the board of directors (the “**Board**”) of Nurosene Health Inc. (the “**Company**”) to which the Board has delegated its responsibility for the oversight of the following:

- nature and scope of the annual audit;
- management’s reporting on internal accounting standards and practices;
- the review of financial information, accounting systems and procedures;
- financial reporting and financial statements,

and has charged the Committee with the responsibility of recommending, for approval of the Board, the audited financial statements, interim financial statements and other mandatory disclosure releases containing financial information.

The primary objectives of the Committee, with respect to the Company and its subsidiaries, are as follows:

- to assist the directors of the Company (the “**Directors**”) in meeting their responsibilities in respect of the preparation and disclosure of the financial statements of the Company and related matters;
- to provide an open avenue of communication among the Company’s auditors, financial and senior management and the Board;
- to ensure the external auditors’ independence and review and appraise their performance;
- to increase the credibility and objectivity of financial reports; and
- to strengthen the role of the outside Directors by facilitating in depth discussions between Directors on the Committee, management and external auditors.

2. Composition

The Committee will be comprised of at least three Directors or such greater number as the Board may determine from time to time and all members of the Committee shall be “independent” (as such term is used in National Instrument 52-110 – *Audit Committees* (“**NI 52-110**”)) unless the Board determines that an exemption contained in NI 52-110 is available and determines to rely thereon. “**Independent**” generally means free from any business or other direct or indirect material relationship with the Company that could, in the view of the Board, reasonably interfere with the exercise of the member’s independent judgment.

All of the members of the Committee must be “financially literate” (as defined in NI 52-110) unless the Board determines that an exemption under NI 52-110 from such requirement in respect of any particular member is available and determines to rely thereon in accordance with the provisions of NI 52-110. Being “**financially literate**” means members have the ability to read and understand a set of financial statements that present a breadth and level of complexity of accounting issues that are generally comparable to the breadth and complexity of issues that can reasonably be expected to be raised by the Company’s financial statements.

The Board shall from time to time designate one of the members of the Committee to be the chairperson of the Committee (the “**Chair**”).

3. Meetings and Administrative Matters

- (a) The Committee shall meet at least four times per year and/or as deemed appropriate by the Committee Chair. As part of its job to foster open communication, the Committee will meet at least annually with management and the external auditors in separate sessions, and at such other times as the external auditor and/or the Committee consider appropriate. The Chief Financial Officer of the Company shall attend meetings of the Committee, unless otherwise excused from all or part of any such meeting by the Chair.
- (b) Agendas, with input from management and approved by the Chair, shall be circulated to Committee members and relevant management personnel along with background information on a timely basis prior to the Committee meetings.
- (c) A quorum for meetings of the Committee will be a majority of its members, and the rules for calling, holding, conducting and adjourning meetings of the Committee will be the same as those governing the Board unless otherwise determined by the Committee or the Board.
- (d) The Chair will preside at all meetings of the Committee, unless the Chair is not present, in which case the members of the Committee that are present will designate from among such members the Chair for purposes of the meeting.
- (e) At all meetings of the Committee, every resolution shall be decided by a majority of the votes cast. In case of an equality of votes, the Chair of the meeting shall be entitled to a second or casting vote.
- (f) The minutes of the Committee meetings shall accurately record the decisions reached and shall be distributed to the Committee members with copies to the Board, the Chief Financial Officer or such other officer acting in that capacity, and the external auditor.
- (g) The Committee may invite such officers, directors and employees of the Company and its subsidiaries, if any, as it sees fit from time to time to attend at meetings of the Committee and assist in the discussion and consideration of the matters being considered by the Committee.
- (h) The Committee may retain persons having special expertise and/or obtain independent professional advice to assist in fulfilling its responsibilities at the expense of the Company as determined by the Committee without any further approval of the Board.
- (i) Any members of the Committee may be removed or replaced at any time by the Board and will cease to be a member of the Committee as soon as such member ceases to be a Director. The Board may fill vacancies on the Committee by appointment from among its members. If and whenever a vacancy exists on the Committee, the remaining members may exercise all its powers so long as a quorum remains. Subject to the foregoing, following appointment as a member of the Committee each member will hold such office until the Committee is reconstituted.
- (j) Any issues arising from these meetings that bear on the relationship between the Board and management should be communicated to the Chairman of the Board by the Committee Chair.

4. Mandate and Responsibilities

To fulfill its responsibilities and duties, the Committee shall:

- (a) undertake annually a review of this mandate and make recommendations to the Corporate

Governance and Nominating Committee as to proposed changes;

- (b) satisfy itself on behalf of the Board with respect to the Company's internal control systems, including, where applicable, relating to derivative instruments:
 - (i) identifying, monitoring and mitigating business risks; and
 - (ii) ensuring compliance with legal, ethical and regulatory requirements;
- (c) review the Company's financial statements and reports and any related management's discussion and analysis ("MD&A"), any annual earnings, interim earnings and press releases before the Company publicly discloses this information and any reports or other financial information (including quarterly financial reports), which are submitted to any governmental body, or to the public, including any certification, report, opinion, or review rendered by the external auditors; the process should include but not be limited to:
 - (i) reviewing changes in accounting principles and policies, or in their application, which may have a material impact on the current or future years' financial statements;
 - (ii) reviewing significant accruals, reserves or other estimates such as the ceiling test calculation;
 - (iii) reviewing accounting treatment of unusual or non-recurring transactions;
 - (iv) ascertaining compliance with covenants under loan agreements;
 - (v) reviewing financial reporting relating to asset retirement obligations;
 - (vi) reviewing disclosure requirements for commitments and contingencies;
 - (vii) reviewing adjustments raised by the external auditors, whether or not included in the financial statements;
 - (viii) reviewing unresolved differences between management and the external auditors;
 - (ix) obtain explanations of significant variances with comparative reporting periods; and
 - (x) determine through inquiry if there are any related party transactions and ensure the nature and extent of such transactions are properly disclosed;
- (d) review the financial reports and related information included in prospectuses, MD&A, information circular-proxy statements and annual information forms and all public disclosure containing audited or unaudited financial information (including, without limitation, annual and interim press releases and any other press releases disclosing earnings or financial results) before release and prior to Board approval. The Committee must be satisfied that adequate procedures are in place for the review of the Company's disclosure of all other financial information and will periodically assess the adequacy of those procedures;
- (e) with respect to the appointment of external auditors by the Board:
 - (i) require the external auditors to report directly to the Committee;
 - (ii) review annually the performance of the external auditors who shall be ultimately accountable to the Board and the Committee as representatives of the shareholders of the Company;

- (iii) obtain annually, a formal written statement of external auditors setting forth all relationships between the external auditors and the Company and confirming their independence from the Company;
 - (iv) review and discuss with the external auditors any disclosed relationships or services that may impact the objectivity and independence of the external auditors;
 - (v) be directly responsible for overseeing the work of the external auditors engaged for the purpose of issuing an auditors' report or performing other audit, review or attest services for the Company, including the resolution of disagreements between management and the external auditor regarding financial reporting;
 - (vi) review management's recommendation for the appointment of external auditors and recommend to the Board appointment of external auditors and the compensation of the external auditors;
 - (vii) review the terms of engagement of the external auditors, including the appropriateness and reasonableness of the auditors' fees;
 - (viii) when there is to be a change in auditors, review the issues related to the change and the information to be included in the required notice to securities regulators of such change;
 - (ix) take, or recommend that the full Board take, appropriate action to oversee the independence of the external auditors;
 - (x) at each meeting, consult with the external auditors, without the presence of management, about the quality of the Company's accounting principles, internal controls and the completeness and accuracy of the Company's financial reports;
- (f) review and approve the Company's hiring policies regarding partners, employees and former partners and employees of the present and former external auditors of the Company;
- (g) review annually with the external auditors their plan for their audit and, upon completion of the audit, their reports upon the financial reports of the Company and its subsidiaries;
- (h) review and pre-approve all audit and audit-related services and the fees and other compensation related thereto, and any non-audit services, provided by the Company's external auditors and consider the impact on the independence of the auditors; The pre-approval requirement is waived with respect to the provision of non-audit services if:
- (i) the aggregate amount of all such non-audit services provided to the Company constitutes not more than five percent (5%) of the total amount of fees paid by the Company to its external auditors during the fiscal year in which the non-audit services are provided;
 - (ii) such services were not recognized by the Company at the time of the engagement to be non-audit services; and
 - (iii) such services are promptly brought to the attention of the Committee by the Company and approved prior to the completion of the audit by the Committee or by one or more members of the Committee who are members of the Board to whom authority to grant such approvals has been delegated by the Committee;

provided the pre-approval of the non-audit services is presented to the Committee's first scheduled

meeting following such approval, such authority may be delegated by the Committee to one or more independent members of the Committee;

- (i) review any other matters that the Audit Committee feels are important to its mandate or that the Board chooses to delegate to it;
- (j) with respect to the financial reporting process:
 - (i) in consultation with the external auditors, review with management the integrity of the Company's financial reporting process, both internal and external;
 - (ii) consider the external auditors' judgments about the quality and appropriateness of the Company's accounting principles as applied in its financial reporting;
 - (iii) consider and approve, if appropriate, changes to the Company's auditing and accounting principles and practices as suggested by the external auditors and management;
 - (iv) review significant judgments made by management in the preparation of the financial reports and the view of the external auditors as to appropriateness of such judgments;
 - (v) following completion of the annual audit, review separately with management and the external auditors any significant difficulties encountered during the course of the audit, including any restrictions on the scope of work or access to required information;
 - (vi) review any significant disagreement among management and the external auditors regarding financial reporting;
 - (vii) review with the external auditors and management the extent to which changes and improvements in financial or accounting practices have been implemented; and
 - (viii) review the certification process,
- (k) review financial reporting relating to risk exposure and risk management policies and procedures of the Company (i.e., hedging, litigation and insurance),
- (l) establish a procedure for:
 - (i) the receipt, retention and treatment of complaints received by the Company regarding accounting, internal accounting controls or auditing matters; and
 - (ii) the confidential, anonymous submission by employees of the Company of concerns regarding questionable accounting or auditing matters.

5. Authority

Following each meeting, in addition to a verbal report, the Committee will report to the Board by way of providing copies of the minutes of such Committee meeting at the next Board meeting after a meeting is held (these may still be in draft form).

Supporting schedules and information reviewed by the Committee shall be available for examination by any director.

The Committee shall have the authority to investigate any financial activity of the Company and to communicate directly with the internal and external auditors. All employees are to cooperate as requested

by the Committee.

The Committee may retain, and set and pay the compensation for, persons having special expertise and/or obtain independent professional advice to assist in fulfilling its duties and responsibilities at the expense of the Company.